Clinical Trial Information
More information about Akcea’s clinical trials is available at clinicaltrials.gov.
- For APPROACH Open Label Study (FCS) information, click here.
- For BROADEN Study (FPL) information, click here.
Tools for Your Practice
Beyond the development of potential new treatments, Akcea is committed to supporting patients and health care professionals with informational resources.
For more information about FCS, please visit FCSFocus.com
As part of Akcea’s commitment to FCS education and the patient perspective please use these links to view expert presentations and patient interviews:
hATTR Guide provides education and resources to empower healthcare professionals to diagnose, manage and better support their patients living with hATTR amyloidosis. To learn more about supporting hATTR amyloidosis patients, including identifying the red-flag symptoms; and diagnosing, managing, and treating the disease, visit hattrguide.com or the hATTR Guide Twitter page.
Akcea and Ambry Genetics are partnering to offer no-cost confidential genetic testing and genetic counseling to patients suspected of having or clinically diagnosed with hATTR amyloidosis through the hATTR Compass Program. To learn more, visit hattrcompass.com.
Additional resources, including a list of advocacy organizations, are available here.
Connect with the Akcea team at an upcoming medical meeting.
American Academy of Neurology
Los Angeles, CA April 21-27
National Lipid Association
Indianapolis, IN, August 11-13
Endocrine Society Clinical Education Update
Chicago, IL, September 23-25
Cardiometabolic Health Congress
Boston, MA, October 4-7
British Cardiovascular Society
Manchester, England, June 5-7
Warwick, England, July 5-7
European Society of Cardiology
Barcelona, Spain, August 26-30
British Endocrine Society
Harrogate, England, November 6-8
International Society of Amyloidosis
Kumamoto, Japan, March 26-29